Immuneering (IMRX)
(Delayed Data from NSDQ)
$1.20 USD
+0.09 (8.11%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $1.20 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Immuneering Corporation (IMRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$11.64 | $25.00 | $1.50 | 948.65% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Immuneering Corporation comes to $11.64. The forecasts range from a low of $1.50 to a high of $25.00. The average price target represents an increase of 948.65% from the last closing price of $1.11.
Analyst Price Targets (7 )
Broker Rating
Immuneering Corporation currently has an average brokerage recommendation (ABR) of 1.88 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.88 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 50% and 12.5% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 12.5%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/IMRX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 3 | 3 | 3 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.88 | 1.88 | 1.88 | 2.00 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/2/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Strong Buy | Strong Buy |
3/15/2024 | Not Identified | Not Identified | Strong Buy | Hold |
3/15/2024 | Guggenheim Securities | Michael Schmidt | Not Available | Hold |
3/15/2024 | Chardan Capital Markets | Geulah Livshits | Strong Buy | Strong Buy |
3/5/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/4/2024 | Needham & Company | Ami Fadia | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.88 |
ABR (Last week) | 1.88 |
# of Recs in ABR | 8 |
Average Target Price | $11.64 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | -0.51 |